
Downloaded from: http://e-space.mmu.ac.uk/622744/

Version: Published Version

Publisher: American Society of Hematology

DOI: https://doi.org/10.1182/bloodadvances.2017011999

Please cite the published version
Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib

The Bruton tyrosine kinase (Btk) inhibitor ibrutinib induces platelet dysfunction and causes increased risk of bleeding. Off-target inhibition of Tec is believed to contribute to platelet dysfunction and other side effects of ibrutinib. The second-generation Btk inhibitor acalabrutinib was developed with improved specificity for Btk over Tec. We investigated platelet function in patients with non-Hodgkin lymphoma (NHL) receiving ibrutinib or acalabrutinib by aggregometry and by measuring thrombus formation on collagen under arterial shear. Both patient groups had similarly dysfunctional aggregation responses to collagen and collagen-related peptide, and comparison with mechanistic experiments in which platelets from healthy donors were treated with the Btk inhibitors suggested that both drugs inhibit platelet Btk and Tec at physiological concentrations. Only ibrutinib caused dysfunctional thrombus formation, whereas size and morphology of thrombi following acalabrutinib treatment were of normal size and morphology. We found that ibrutinib but not acalabrutinib inhibited Src family kinases, which have a critical role in platelet adhesion to collagen that is likely to underpin unstable thrombus formation observed in ibrutinib patients. We found that platelet function was enhanced by increasing levels of von Willebrand factor (VWF) and factor VIII (FVIII) ex vivo by addition of intermediate purity FVIII (Haemate P) to blood from patients, resulting in consistently larger thrombi. We conclude that acalabrutinib avoids major platelet dysfunction associated with ibrutinib therapy, and platelet function may be enhanced in patients with B-cell NHL by increasing plasma VWF and FVIII.

Introduction

The Bruton tyrosine kinase (Btk) inhibitor ibrutinib was the first of a new class of drug for the treatment of indolent non-Hodgkin lymphomas (NHLs). Treatment with ibrutinib has proven to be efficacious but is associated with side effects, including increased risk of major bleeding. Bleeding associated with ibrutinib is potentially explained by off-target inhibition of other kinases in addition to Btk; a study of patients with X-linked agammaglobulinemia (XLA), who have Btk deficiency, reported no increased risk of bleeding although genetic deficiency of Btk was found to increase time occlusion in a mouse model of carotid artery injury. Furthermore, studies performed using genetically modified mice demonstrated redundancy between Btk and Tec in platelet signaling because ablation of both kinases was required to
render platelets fully insensitive to collagen in aggregation assays.\(^5\) The effect of simultaneous genetic ablation of Btk and Tec on platelet adhesion under shear has not been explored in vivo or in vitro. The off-target effects of ibrutinib on platelet function have added complications to its use, such as risks associated with concurrent treatment with anticoagulant or antiplatelet medication, which is common among patients with chronic lymphocytic leukemia (CLL).\(^6\) Ibrutinib therapy is interrupted before surgery to reduce the risk of bleeding, but prolonged dose interruption or dose reduction may reduce efficacy and lead to a flare in symptoms.\(^7\) Acalabrutinib is a second-generation Btk inhibitor and exhibits greater selectivity over kinases that are important for platelet function such as Src family kinases (SFKs) and Tec.\(^8\) No major bleeding events were reported during a phase 2 trial of acalabrutinib for treatment of CLL,\(^8\) but it is not yet clear if the selectivity of acalabrutinib is sufficient to fully avoid the platelet dysfunction associated with ibrutinib.

Ibrutinib causes platelet dysfunction downstream of the GPVI receptor, GP1b, and integrin \(\alpha_{\text{IIb}}\beta_3\).\(^9-11\) Although XLA is not associated with increased risk of bleeding, deficient expression or function of GPVI,\(^12-14\) GP1b,\(^15\) or integrin \(\alpha_{\text{IIb}}\beta_3\)\(^16\) is associated with bleeding phenotypes in mice or humans. The precise reason for the discrepancy between bleeding risk in patients with XLA and patients receiving ibrutinib has not been characterized, but is thought to relate to off-target inhibition of Tec.\(^8\) However, ibrutinib may also inhibit other important platelet kinases such as SFK that phosphorylate several signaling molecules in the GPVI signaling pathway.\(^17\) Btk and Tec are themselves dependent on SFK-mediated tyrosine phosphorylation to become active.\(^18,19\) Inhibition of SFK is known to cause hemostatic dysfunction because the Src inhibitor, dasatinib, is associated with increased bleeding risk.\(^20-22\) Comparison of ibrutinib and acalabrutinib therapy therefore represents an important opportunity to characterize their relative effects and understand how improved kinase specificity affects platelet dysfunction.

Thrombocytopenia is frequently associated with CLL and may be a contributing factor to bleeding events in combination with drug-induced platelet dysfunction.\(^23,24\) Treatment options for patients that are at high risk of bleeding are currently limited and the clinical efficacy of platelet transfusion has not been established.\(^2\) Evidence that platelet transfusion may reverse platelet dysfunction caused by ibrutinib is based on in vitro data\(^11\) with few studies investigating this approach clinically.\(^25\) Furthermore, the benefit of platelet transfusion during treatment with other antiplatelet medication is

<table>
<thead>
<tr>
<th>Table 1. Patient information</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Acalabrutinib 100 mg BD (n = 8)</strong></td>
</tr>
<tr>
<td><strong>Age, median (range), y</strong></td>
</tr>
<tr>
<td><strong>Sex, n (%)</strong></td>
</tr>
<tr>
<td>Female</td>
</tr>
<tr>
<td>Male</td>
</tr>
<tr>
<td><strong>Diagnosis, n (%)</strong></td>
</tr>
<tr>
<td>CLL</td>
</tr>
<tr>
<td>Mantle cell lymphoma</td>
</tr>
<tr>
<td><strong>Laboratory parameters</strong></td>
</tr>
<tr>
<td>Hemoglobin, median (range), g/L</td>
</tr>
<tr>
<td>Platelet count, median (range), (\times 10^9/L)</td>
</tr>
<tr>
<td><strong>Clinical details, n (%)</strong></td>
</tr>
<tr>
<td>Concurrent antplatelet drugs</td>
</tr>
<tr>
<td>Concurrent anticoagulants</td>
</tr>
<tr>
<td>Inherited bleeding disorders</td>
</tr>
<tr>
<td>Duration of Btk inhibitor, median (range), mo</td>
</tr>
<tr>
<td>Active bleeding at time of recruitment</td>
</tr>
<tr>
<td><strong>Bleeding on Btk inhibitor, n (%)†</strong></td>
</tr>
<tr>
<td>None</td>
</tr>
<tr>
<td>Grade 1</td>
</tr>
<tr>
<td>Grade 2</td>
</tr>
<tr>
<td><strong>Response to Btk inhibitor, n (%)‡</strong></td>
</tr>
<tr>
<td>Complete remission</td>
</tr>
<tr>
<td>Partial remission</td>
</tr>
<tr>
<td>Stable or progressive disease</td>
</tr>
</tbody>
</table>

BD, twice daily; OD, once daily.
*Dabigatran 150 mg twice daily.
†Common Terminology Criteria for Adverse Events grading scale.
‡International Workshop on Chronic Lymphocytic Leukemia criteria for chronic lymphocytic leukemia; positron emission tomography computed tomography criteria for mantle cell lymphoma.
Figure 1. Acalabrutinib and ibrutinib therapy cause dysfunctional GPVI-mediated platelet aggregation. PRP from patients receiving ibrutinib (Ibr; n = 6), acalabrutinib (Acal; n = 7), healthy donors (n = 9), or Btk inhibitor naive CLL patients (n = 5) was loaded into 96-well microtiter plates containing lyophilized platelet agonists. Plates were shaken for 5 minutes at 37°C and aggregation was measure by light transmission to give an end point measurement. (A) Scatter plot of EC50 values calculated from

---

**Figure 1. Acalabrutinib and ibrutinib therapy cause dysfunctional GPVI-mediated platelet aggregation.** PRP from patients receiving ibrutinib (Ibr; n = 6), acalabrutinib (Acal; n = 7), healthy donors (n = 9), or Btk inhibitor naive CLL patients (n = 5) was loaded into 96-well microtiter plates containing lyophilized platelet agonists. Plates were shaken for 5 minutes at 37°C and aggregation was measured by light transmission to give an end point measurement. (A) Scatter plot of EC50 values calculated from
controversial and may lead to poorer outcomes. Investigating alternatives to platelet transfusion to treat or prevent bleeding during ibrutinib or acalabrutinib therapy is therefore a priority. One alternative to platelet transfusion for bleeding patients, or those undergoing surgery and at risk of bleeding from platelet dysfunction, is administration of desmopressin, which stimulates secretion of the contents of Weibel-Palade bodies and results in an acute increase in plasma von Willebrand factor (VWF) and factor VIII (FVIII) levels of two- to sixfold. Indeed, successful administration of desmopressin to stop bleeding in patients suffering from thrombocytopenia has also been reported. It may be possible to administer desmopressin to treat bleeding or reduce bleeding risk during treatment with Btk inhibitors, either as an alternative for or adjunct to platelet transfusion. However, because ibrutinib inhibits GP Ib-mediated platelet function, it has remained unclear if this approach might be beneficial.

**Methods**

**Materials**

Type I collagen was obtained from Nycomed (Munich, Germany) and collagen-related peptide (CRP-XL) from Professor Richard Farndale (University of Cambridge, Cambridge, United Kingdom). Adenosine 5'-diphosphate (ADP), arachidonic acid, and U46619 were from Sigma (Gillingham, United Kingdom), and TRAP-6 epinephrine was from Labmedics (Salford, United Kingdom). Acalabrutinib, ibrutinib, and dasatinib were from Selleckchem (Munich, Germany). Antiphosphotyrosine antibody 4G10 was obtained from Millipore (Burlington, MA). PKC substrate antibody and phospho-PLCγ2 Y759 was from New England Biolabs (Hitchin, United Kingdom). Phospho-Src 418 antibody and Fura-2 am was from Life Technologies (Paisley, United Kingdom). Phospho-Btk Y223, phospho-Lyn Y396, and phospho-β3 Y773 antibodies were from Abcam (Cambridge, United Kingdom). Actin antibody was from Santa Cruz Biotechnology (Heidelberg, Germany). Greene 96-well plates and DiOC6 were from Thermo Fisher Scientific (Dartford, United Kingdom).

**Patients.** Trough blood samples were obtained from patients with CLL or mantle cell leukemia and receiving either ibrutinib (6 patients) or acalabrutinib (8 patients; Table 1). Our control group comprised Btk-inhibitor naive CLL patients (5 patients). All patients provided informed consent in accordance with the declaration of Helsinki. Ethics approval for this study was covered under the Oxford Radcliffe Biobank research tissue bank ethics, HTA License Number 12217, Oxfordshire C REC: 09/H0606/5+5, project approval code 17/A016.

**Platelet preparation.** Blood samples were obtained from healthy donors that had given informed consent and using procedures approved by the University of Reading Research Ethics Committee or from patients and collected into vacutainers containing 3.8% (w/v) sodium citrate. Platelet-rich plasma (PRP) was prepared by centrifuging whole blood at 100g for 20 minutes. Washed platelets were prepared by adding acid citrate dextrose to PRP and centrifuging at 350g for 20 minutes and resuspending the platelet pellet at 4×10^8 cells/mL in Tyrode’s buffer as previously described.

**Platelet-based aggregometry.** For measurement of aggregation using PRP from patients or healthy donors, 96-well plates (Greiner) containing the following freeze-dried platelet agonists at a range of concentrations: ADP, CRP-XL, epinephrine, U46619, collagen, and TRAP-6 were prepared in advance and stored in vacuum sealed bags for no more than 2 months. PRP isolated from the blood of healthy donors or patients was loaded onto plates and shaken at 1200 rpm for 5 minutes at 37°C using a plate shaker (Quantifoil Instruments), as described by Lordkipanidze et al; absorption of 405 nm light was measured using a Multiskan Ascent 354 Microplate Reader (LabSystems). Aggregation of washed platelets was performed in 96-well plates as previously described.

**Thrombus formation under flow.** Thrombus formation was performed using blood from healthy donors using microfluidic flow chips (Vena8, Cellix Ltd, Dublin, Ireland) coated with 100 μg/mL type I collagen and measured in real time following incubation of blood from healthy donors with ibrutinib, acalabrutinib, or vehicle for 10 minutes, or fixed with 10% formal saline after 8 minutes of perfusion at a shear rate of 1000 s⁻¹ and imaged at a later time.

**Protein phosphorylation studies.** Washed platelets at 4×10⁸ cells per milliliter in the presence of inhibitors to prevent aggregation (100 μM MRS2179, 1 μM cangrelor, 10 μM indomethacin, and 1 mM EGTA) were incubated with ibrutinib or acalabrutinib at concentrations specified in individual figures or vehicle for 5 minutes at 37°C before addition of 1 μg/mL CRP-XL. Samples were incubated for 3 minutes with stirring at 37°C using an aggregometer (Helena) before addition of reducing Laemmli sample treatment buffer.

**Phospho-Tec ELISA.** Platelets were prepared and stimulated as detailed previously but lysed in NP40 buffer (300 mM NaCl, 20 mM Tris base, 2 mM EDTA, 1 mM PMSF, 10 μg/mL aprotinin, 10 μg/mL leupeptin, 0.7 μg/mL pepstatin A, 2 mM sodium orthovanadate, 2% v/v NP-40; pH 7.3) and analyzed using a human phosphotyrosine Tec enzyme-linked immunosorbent assay (ELISA kit, RayBio). Absorption at 405 nm was measured using a NOVOSTar plate reader (BMG LabTech, Aylesbury, United Kingdom).

**Ca²⁺ measurement.** The [Ca²⁺]i assay was performed at 37°C using fura-2 loaded washed platelets in black 96-well plates (Greiner). Dual excitation was measured using a Novostar spectrofluorometer (BMG Labtech) previously described.

**Platelet adhesion to collagen.** Washed platelets at 2×10⁷ cells/mL were exposed to collagen (100 μg/mL)-coated, 96-well assay plates, and allowed to adhere for 45 minutes at 37°C. Nonadherent platelets were washed off before, fixed with 10% formal saline for 10 minutes. The wells were then washed and labeled with DiOC6. Fluorescence images of adherent platelets were captured with the 20× objective lens of an ImageXpress Nano high content imaging system and counted using CellReporterXpress software (Molecular Devices, Winnersh, United Kingdom).

Figure 1. (continued) concentration response curves for ADP, U46619, epinephrine, TRAP-6, CRP-XL, and collagen. Each point represents the response of a patient receiving acalabrutinib (red triangle) or ibrutinib (green square); healthy donor (gray circle); NR, patients that did not respond to an agonist at the highest concentration tested. Concentration response curves for GP Ib agonists (B) CRP-XL and (C) collagen; each point represents the mean % aggregation values ± standard error of the mean (SEM). Significant differences relative to healthy donors were tested by 2-way ANOVA with the Turkey multiple comparisons test. Aggregation of washed platelets from healthy donors pre-treated with a range of (D) acalabrutinib or (E) ibrutinib concentrations and then stimulated with 3 to 0.01 μg/mL CRP-XL.
Figure 2. SFK activation and adhesion to collagen is spared by acalabrutinib but not ibrutinib. Washed human platelets from healthy donors were preincubated with a range of (A) acalabrutinib or (B) ibrutinib and then stimulated with 1 μg/mL CRP-XL for 3 minutes at 37°C; tyrosine phosphorylation of Src (Y418) and Btk (Y223) were measured by western blot using site-specific antibodies and total levels of Tec tyrosine phosphorylation were measure by ELISA. Points represent mean levels of tyrosine phosphorylation relative to vehicle-treated controls ± SEM. (C) Representative images of phosphoblots. Washed platelets treated with a range of acalabrutinib, ibrutinib, or dasatinib concentrations and stimulated as previously and blotted for (D) tyrosine phosphorylation of Lyn (Y396) or (E) total phosphotyrosine using a site-specific antibody or 4G10, respectively. Points represent mean levels of tyrosine phosphorylation relative to vehicle-treated controls ± SEM. (F) Aggregation 1 μg/ml CRP-XL stimulated of washed platelets was performed in 96-well plates after treatment with a range of concentrations of acalabrutinib, ibrutinib, or dasatinib concentration response curves are mean platelet
**Fluorescence-activated cell sorting measurement of fibrinogen binding and p-selectin exposure.** Measurements of fibrinogen binding and p-selectin exposure were performed using washed platelets pretreated with inhibitors as described in figure legends and stimulated with 1 μg/mL CRP in the presence of fluorescent isothiocyanate–conjugated polyclonal rabbit anti-fibrinogen antibody (Agilent Technologies LDA UK Limited, Cheadle, United Kingdom) and PE-Cy5-conjugated mouse anti-P-selectin (CD62P) antibody (BD, Berkshire, United Kingdom), and then incubated for 20 minutes in the dark. Platelets were then fixed by addition of filtered formyl saline (0.2% formaldehyde in 0.15M NaCl) and median fluorescence intensities were measured for 5000 platelets per sample on an Accuri C6 Flow Cytometer (BD Biosciences, Berkshire, United Kingdom).

**Statistical methods.** Statistical testing as described in figure legends and the results section were performed using GraphPad Prism Software (GraphPad, La Jolla, CA).

**Results**

**Acalabrutinib and ibrutinib cause dysfunction of GPVI-mediated platelet aggregation**

Platelet aggregation to GPVI agonists has previously been shown to be inhibited in blood samples taken from patients receiving ibrutinib, but the effect of acalabrutinib on platelet function has not been reported. Aggregation of PRP was used to characterize platelet function of patients treated with ibrutinib or acalabrutinib (Table 1). One patient receiving acalabrutinib was excluded from this aspect of the study because of a low platelet count (<50 x 10^9/L). The aggregation assay included ADP, U46619, epinephrine, thrombin receptor activator peptide-6 (TRAP-6), CRP-XL, and collagen was adapted from the method developed and validated by Lordkipanidze et al. We used a range of agonist concentrations to enable comparison of patient sensitivity to each agonist by estimation of the log half maximal effective concentration (logEC50) by nonlinear regression analysis. Results were compared with a group of healthy donors and Btk inhibitor naïve CLL patients (Figure 1A). Aggregation stimulated by ADP, U46619, epinephrine, and TRAP-6 was not significantly different in either patient group compared with healthy controls. Responses to collagen were completely ablated in all patients tested for both patient groups receiving Btk inhibitors, even at the highest concentration of collagen (3 μg/mL) (Figure 1A-B). Responses to the GPVI receptor agonist CRP-XL were either less potent (ibrutinib, 2 patients; acalabrutinib, 3 patients) or ablated (ibrutinib, 4 patients; acalabrutinib, 4 patients) relative to responses of healthy controls (logEC50 = –7.7M ± 0.30; Figure 1C) and Btk inhibitor naïve CLL patients (logEC50 = –7.3M ± 0.38). Experiments in which CRP-XL was titrated against ibrutinib and acalabrutinib indicated that 10 μM acalabrutinib or 1 μM ibrutinib was required to ablate platelet aggregation of washed platelets from healthy donors (Figure 1D-E).

**Acalabrutinib is selective for SFK but not Tec**

Both ibrutinib and acalabrutinib have been screened for activity against a panel of kinases in cell-free, in vitro assays. However, the estimated potency of the drugs in such assays does not correspond closely with measurements performed in cell-based assays. In addition to this, kinase regulation in the platelet is highly complex and involves positive and negative feedback mechanisms. To elucidate the mechanistic differences between ibrutinib and acalabrutinib that underpin differences in bleeding risk, we characterized the effects of the drugs on phosphorylation events downstream of GPVI in platelets from healthy donors (Figure 2). Phosphorylation of Btk Y223, the autoprophosphorylation site of Btk that correlates with its kinase activity, was inhibited with equal potency by ibrutinib (log half maximal inhibitory concentration [logIC50] = –7.2M ± 0.30) and acalabrutinib (logIC50 = –7.1M ± 0.21; Figure 2A-B). Inhibition of Tec was harder to quantify because of the lack of site-specific phospho antibodies, but total phosphotyrosine levels can be measured by ELISA. Total Tec phosphotyrosine levels are likely to include the Tec autophosphorylation site Y418 as well as tyrosine residues phosphorylated by other kinases such as SFK. We estimated that Tec was more potently inhibited by ibrutinib (logIC50 = –6.4M) than by acalabrutinib (logIC50 = –5.5M; Figure 2A-B); however, the concentration-response profiles of both ibrutinib and acalabrutinib were complex, involving both positive and negative components and differential regulation of multiple sites. Phosphorylation of the autophosphorylation site Y418 of Src appeared to be potentiated by both drugs at lower concentrations. However, at higher concentrations, ibrutinib also inhibited Src Y418 phosphorylation (logIC50 = –5.7M ± 0.18), whereas acalabrutinib did not inhibit Src activity and actually potentiated activation even at high concentrations (logEC50 = –7.5M ± 0.46; Figure 2A-B). Because our data indicated that platelet Btk and Tec were likely to be inhibited by physiological concentrations of both ibrutinib and acalabrutinib, we further investigated inhibition of SFK by comparing both drugs to the SFK inhibitor dasatinib. Phosphorylation of Lyn Y396 (Figure 2D) was ablated by dasatinib (logIC50 = –7.1M ± 0.05) and ibrutinib (logEC50 = –5.8M ± 0.08) but not acalabrutinib, which only inhibited phosphorylation to 70% of vehicle-treated platelets at the highest concentration tested (10 µM). Total phosphotyrosine levels (Figure 2E) followed a similar pattern whereby dasatinib caused near ablation of CRP-XL–evoked tyrosine phosphorylation (logIC50 = –6.9M ± 0.24), whereas ibrutinib was less potent (logIC50 = –5.1M ± 0.29) and acalabrutinib only inhibited partially (71.7% of vehicle) at 10 µM.

**Ibrutinib but not acalabrutinib potently inhibits platelet adhesion to collagen**

Aggregation of washed platelets evoked by 1 μg/mL CRP-XL was completely ablated by acalabrutinib (logIC50 = –5.3M ± 0.06) and with significantly greater potency by ibrutinib (logIC50 = –6.2M ± 0.28) and dasatinib (logIC50 = –6.6M ± 0.6; Figure 2F). We have previously reported that discrepancies are present in the way that ibrutinib inhibits platelet aggregation to immobilized collagen-coated surfaces. Adhesion of platelets to collagen (Figure 2G) was...
Acalabrutinib inhibits signal transduction downstream of GPVI with lower potency than ibrutinib. Washed human platelets from healthy donors were preincubated with a range of acalabrutinib or ibrutinib concentrations and then stimulated with 1 μg/mL CRP-XL for 3 minutes at 37°C and phosphorylation of (A) PLCγ2.
Acalabrutinib is a less potent inhibitor of integrin αIIbβ3 activation and granule secretion than ibrutinib. Washed human platelets from healthy donors were preincubated with a range of acalabrutinib or ibrutinib concentrations and then stimulated with 1 μg/mL CRP-XL for 20 minutes. (A) P-selectin and (B) fibrinogen binding was measured by fluorescence-activated cell sorting. (C) Platelets were stimulated with 1 μg/mL CRP-XL for 3 minutes at 37°C. Phosphorylation of β3 (Y773) was measured by western blotting. Points represent mean responses relative to vehicle ± SEM. (D) Representative β3 (Y773) blots.

Acalabrutinib inhibits signaling downstream of GPVI less potently than ibrutinib

To understand the consequences of the differences in kinase specificity of the inhibitors, signaling events downstream of the kinases were measured. We found that phosphorylation of the Btk substrate, Y759 of PLCγ2, was inhibited by both ibrutinib (logIC50 = -5.9M ± 0.18) and acalabrutinib (logIC50 = -6.7 ± 0.26; Figure 3B). However, acalabrutinib did not completely ablate phosphorylation of PLCγ2 Y759 even at the highest concentration of acalabrutinib tested. Phosphorylation of PKC substrates was partially inhibited (~40% of vehicle) by ibrutinib (logIC50 = -6.9M ± 0.09), which closely matched their ability to inhibit Lyn activity. Acalabrutinib was a weak inhibitor of adhesion to collagen and only reduced the number of adhered platelet to 60% ± 9.4 of vehicle.

Acalabrutinib inhibits secretion downstream of GPVI more potently than ibrutinib

Figure 4. Acalabrutinib is a less potent inhibitor of integrin αIIbβ3 activation and granule secretion than ibrutinib. Phosphorylation of the β3 subunit is a critical event in the initiation of integrin αIIbβ3 outside-in signaling. Phosphorylation of the β3 subunit was more potently inhibited by acalabrutinib (logIC50 = -6.7 ± 0.07) than by ibrutinib (logIC50 = -6.9 ± 0.04, P < .05, Student t test) at the highest concentration tested. Acalabrutinib appeared to be only a partial inhibitor of β3 Y773 phosphorylation, because even at the highest concentration tested, a reduction to only 27% ± 2.5 relative to vehicle was stimulated downstream of PLCγ2 and was also inhibited less potently by acalabrutinib (logIC50 = -6.1M ± 0.08) than ibrutinib (logIC50 = -6.7 ± 0.07, P < .05, Student t test).

Acalabrutinib inhibits secretion following stimulation with CRP-XL

Figure 3. (continued) (Y759) and (B) PKC substrates (S/T) was measured by western blotting. (C) Representative western blot images for PLCγ2 (Y759) and S/T phosphorylated PKC substrates. (D) Cytosolic Ca²⁺ following stimulation with 1 μg/mL CRP-XL was measured in fura-2 loaded platelets in real time for 5 minutes. Points represent the mean response relative to vehicle ± SEM. Representative [Ca²⁺] traces following incubation with (E) acalabrutinib or (F) ibrutinib.
achieved, whereas ibrutinib caused inhibition to 6% ± 1.0 of vehicle.

**Acalabrutinib avoids dysfunctional thrombus formation caused by ibrutinib**

Given the differences in the effects of the drugs on adhesion to collagen compared with GPVI-mediated aggregation, we compared the effects of the drugs on platelet adhesion and thrombus formation in collagen-coated flow chambers under arterial shear conditions. After treating whole blood from healthy donors with either 1 μM ibrutinib or acalabrutinib for 20 minutes, ibrutinib caused reduced thrombus formation (1 μM ibrutinib: 383AU ± 40.1, vehicle 585AU ± 67.6, P < .05, Student t test), whereas in the presence of vehicle or acalabrutinib, thrombus formation was not significantly different (Figure 5A-B). The most striking difference between ibrutinib and acalabrutinib treatment was the lack of stable, retracted thrombi after ibrutinib treatment (Figure 5A). In the presence of vehicle or acalabrutinib, platelets accumulated on collagen fibers while continuously contracting into dense thrombi, whereas ibrutinib prevented retraction of platelet aggregates, which consequently remained unstable, appeared loose, and were prone to disaggregation (supplemental Video 1). The effects of 1 μM ibrutinib and acalabrutinib on several important signaling and functional measurements are summarized in Figure 5B.

To test whether experiments performed using blood from healthy donors matched the effects of drugs at therapeutic concentrations, we performed measurements of thrombus formation on collagen under arterial shear using blood samples from healthy donors, Btk-inhibitor naïve patients, or patients receiving ibrutinib or acalabrutinib (Table 1). Blood from acalabrutinib patients formed morphologically normal thrombi on collagen (Figure 6A), although heterogeneity in platelet counts strongly influenced thrombus volume (Figure 6C). Thrombus volume in acalabrutinib patients with platelet counts >150 × 10⁹/L (78 895 μm³ ± 19 995, P > .05, Student t test) was not significantly different to those of Btk-inhibitor naïve patients (75 608 μm³ ± 19 995, P = .011, Student t test). In contrast, thrombus volume for ibrutinib patients was highly variable and did not correlate with platelet count (Figure 6D). Images of thrombi measured in samples from patients with platelet counts >150 × 10⁹/L are presented in Figure 6A. Samples from 2 of the ibrutinib patients exhibited very pronounced dysfunction whereby platelets formed a loose covering of the majority of the surface of the flow chamber without forming stable thrombi (“large”); Figure 6A), whereas others formed small thrombi (“small”; Figure 6A).
Addition of Haemate P ex vivo to patients’ blood improves platelet function

Thrombus formation assays using patients’ blood were performed in the presence or absence of 2 units/mL of Haemate P. Correlation of thrombus volume with platelet count was not significant within the Btk-inhibitor naïve patient group because platelet counts were all $>100 \times 10^9/L$ and thrombus volume was fairly uniform. The correlation was significant in patients treated with acalabrutinib (Figure 6B), but not in patients treated with ibrutinib (Figure 6C), despite half of the patients having platelet counts $<100 \times 10^9/L$, which strongly influences thrombus volume. Addition of Haemate P significantly increased thrombus volume in healthy donors and patients treated with acalabrutinib or ibrutinib ($P < .05$, 2-way analysis of variance (ANOVA) with repeated measures and the Sidak multiple comparisons test; Figure 7).

Discussion

Ibrutinib has proven to be an effective treatment of low-grade NHL but is associated with an increased risk of bleeding, whereas the effects of the second-generation Btk inhibitor, acalabrutinib, on platelet signaling and function have not been studied in detail. Ibrutinib has been shown to inhibit platelet aggregation evoked by GPVI receptor agonists, but the effects of acalabrutinib therapy on platelet aggregation have not been reported. We found that aggregation evoked by collagen and CRP-XL was either partially or completely inhibited in all patients receiving ibrutinib or acalabrutinib (Figure 1). Peak plasma concentrations of ibrutinib and acalabrutinib have been estimated at approximately 300 nM.
and 1.7 μM, respectively, in vivo,8,36 but our characterization of the concentration-response profile of both drugs in vitro (Figure 1D-E) indicated that a concentration of acalabrutinib corresponding to 3 to 10 μM would be required to achieve the level of inhibition of CRP-XL evoked signaling observed in patients. For this reason, we concluded that the apparent potency of acalabrutinib when measured by treatment of platelets in vitro was lower than that observed in patients. We hypothesize that accumulation of the drugs may occur in platelets because of their irreversible mode of actions and lack of protein turnover in platelets.

Although we found that ibrutinib and acalabrutinib inhibited Btk activity with similar potency, our study of kinase activation downstream of GPVI identified differences in the way the drugs affected SFK and Tec (Figure 2). Although the specificity of both kinases has been characterized in vitro8,33 and ibrutinib has been shown to inhibit SFK and Btk in platelets,9,11 a comprehensive comparison of ibrutinib and acalabrutinib has not previously been reported. We found that activation of Src was potentiated by acalabrutinib and that the concentration-response profile mirrored the inhibition curve for Btk Y223, suggesting that Btk mediates negative feedback regulation on SFK when active. At intermediate concentrations of acalabrutinib, Tec activation was similarly increased, likely as a direct result of the potentiation of Src, which is known to regulate activation of Tec family kinases.37 Ibrutinib caused potentiation over a narrow concentration range because direct inhibition of Tec and Src occurred at intermediate and high concentrations.

Our in vitro experiments indicate that only concentrations of acalabrutinib that inhibit Tec activation (3-10 μM; Figure 2) are able to ablate platelet aggregation evoked by CRP-XL (Figure 1D). Therefore, our observation that CRP-XL-evoked aggregation was strongly inhibited during acalabrutinib therapy (Figure 1) suggested that therapeutic doses of acalabrutinib must inhibit Tec, despite the improvement in selectivity relative to ibrutinib. However, we went on to demonstrate both in vitro and with blood samples from patients receiving ibrutinib or acalabrutinib that only ibrutinib causes severe platelet dysfunction measured by thrombus formation on collagen under conditions of arterial shear (Figure 7). Taken together, these data suggest that Tec family kinase activity is required for CRP-XL-mediated platelet aggregation but is redundant for adhesion and thrombus formation on collagen, which is instead dependent on SFK. We believe that this important distinction underlies the absence of severe platelet dysfunction in patients receiving acalabrutinib and that greater selectivity for Tec family kinases over SKF is likely to be the cause of this difference. Our observation that acalabrutinib did not inhibit SFK, and in fact caused potentiation of SFK activation (Figure 2), may be an important factor in compensating for the loss of Btk kinase activity.

We found that GPVI-mediated platelet aggregation and signaling still occurs when Btk activity is absent, because several functional and signaling events occur at near vehicle-treated levels following treatment with 1 μM acalabrutinib, a concentration that ablates Btk activity (Figure 5). Our data suggest that this may be a direct result of potentiation of signaling through Tec and SFK, which enable Tec to mediate normal levels Ca2+ signaling, PKC and integrin αβ3 activation, and α-granule secretion despite being expressed at approximately eightfold lower levels than Btk in platelets.38 This potentiation mechanism has not previously been reported and may also explain why bleeding risk is not increased in Btk-deficient XLA patients.3

We have previously reported that ibrutinib inhibits integrin αβ3 outside-in signaling, clot retraction, and thrombus stability, attributing this observation to loss of Btk-mediated PLCγ2 activation downstream of integrin αβ3.9 However, in the present study, we found that downstream of GPVI, phosphorylation of β3 Y773, which is the first step in outside-in signaling, was potently inhibited by ibrutinib and acalabrutinib and therefore is likely mediated, at least partially, by Btk.
In healthy donors, only ibrutinib caused a reduction in platelet adhesion to collagen (Figure 5) and inhibited retraction of thrombi (supplemental Video 1). In samples from some patients, ibrutinib caused a striking lack of clot retraction, resulting in the formation of a layer of loosely packed platelets, whereas in others the size of the thromboplast appeared reduced relative to ibrutinib-naive patients with similar platelet counts (Figure 6). The reason for the variability between ibrutinib patients was unclear but may relate to differences in drug concentration or patient physiology; however, thrombus volume did not seem to correlate with sensitivity to CRP-XL measured by aggregometry. Treatment with acalabrutinib did not affect thrombus formation or retraction, however, and platelet count was the major determinant of thrombus volume in these patients (Figure 6).

We studied ex vivo addition of Haemate P to blood from patients with CLL or mantle cell leukemia receiving ibrutinib or acalabrutinib to approximate the increase in levels of VWF and FVIII that might be achieved following administration of desmopressin to a patient that expresses functional VWF, and measured thrombus formation on collagen (Figure 7). We found that Haemate P increased platelet adhesion to collagen in all patients, regardless of treatment type or platelet count. This finding suggests that agents that increase plasma levels of VWF may improve primary hemostasis in CLL patients at increased risk of bleeding either from thrombocytopenia or drug-induced platelet dysfunction. Platelet transfusion has been shown to inhibit adhesion to VWF-coated flow chambers, our experiments demonstrate that VWF still contributes to and enhances thrombus formation on collagen; therefore, our data suggest that this could still be a potentially efficacious treatment of patients treated with ibrutinib. Investigation of platelet function in patients that are currently experiencing bleeding during ibrutinib therapy as well as evaluation to improve platelet function could offer further insights into Btk-inhibitor induced platelet dysfunction and potential treatments. Safety improvements of successive generations of Btk inhibitors combined with a better understanding of treatment options for bleeding may further improve outcomes patients with NHL.

In conclusion, we found that Btk activity is redundant in the context of GPVI-mediated platelet aggregation if Tec is functional, but is lost if both tyrosine kinases are simultaneously inhibited. However, Btk and Tec are redundant for platelet adhesion and thrombus formation on collagen under flow, whereas SFK play a critical role and are inhibited by ibrutinib but not acalabrutinib. Loss of SFK function and inhibition of stable thrombus formation is likely to contribute to bleeding risk in ibrutinib-treated patients, but we found evidence that platelet function could be improved by agents that increase plasma VWF levels.

References


